This proposal seeks to develop a new training program in Translational Cardiovascular Research and Entrepreneurship (CVRE) at the University of Michigan. Cardiovascular disease is the leading cause of death worldwide. Therefore, the mission of this program is to train the next generation of PhD scientists seeking careers in cardiovascular research in the ethical development and application of research results from the level of the molecule, through the cellular, intact tissue and animal models, to the bedside, with the ultimate goal of improving therapy for patients. Since this is a pre-doctoral training experience taking place during the last two years of the PhD program after preliminary examination, the emphasis is on an advanced didactic program and independent research. The proposed training program is intentionally designed to address the gap in training of young basic scientists and pre-doctoral students in key areas of translational cardiovascular research such as preclinical research design, drug discovery, device/therapy development, optimization and testing, entrepreneurship, and regulatory compliance. The interdisciplinary and internationally recognized faculty of this program provides an outstanding training environment that includes state of the art facilities and techniques spanning genetic, molecular, cellular, systems, engineering and clinical investigation of both vascular and cardiac diseases. By capitalizing on the existing strengths of our faculty in basic and preclinical cardiovascular research and unique academic resources at the University of Michigan, we will train students not only in state of the art biomedical research, but also in applying systems biology for preclinical testing, navigating regulatory compliance, and entrepreneurship. Therefore, this program offers students a unique comprehensive and immersive experience in translational research training. The added benefit is that it will also prepare students for the diversity of scientific careers available to and typially pursued by young scientists including academic research, start-up companies, biotechnology and large pharmaceutical and device companies. The translational CVRE program will attract students from laboratories across the Frankel Cardiovascular Center faculty membership, the medical school wide Program in Biomedical Sciences, and the School of Engineering. By placing students at the interface between basic cardiovascular research, biomedical engineering, and cardiovascular medicine, we hope to better prepare the next generation of PhD scientists to be the leaders and best at taking basic research discoveries and being capable of directing their path to the clinic.

Public Health Relevance

Cardiovascular disease is the leading cause of death worldwide. The Cardiovascular Research and Entrepreneurship Training Program is focused on training the next generation of PhD scientists to be capable of both making discoveries in the molecular mechanisms of cardiovascular disease and leading research programs to guide the translation of those discoveries into effective therapies that can be applied in clinical medicine. This new training program will therefore contribute to accelerating the translation of laboratory discoveries into clinical therapies that directly impact our ability to improve treatment of human cardiovascular disease.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Institutional National Research Service Award (T32)
Project #
5T32HL125242-05
Application #
9706917
Study Section
Special Emphasis Panel (ZHL1)
Program Officer
Wang, Wayne C
Project Start
2015-07-01
Project End
2020-06-30
Budget Start
2019-07-01
Budget End
2020-06-30
Support Year
5
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Crouch, A Colleen; Manders, Adam B; Cao, Amos A et al. (2018) Cross-sectional area of the murine aorta linearly increases with increasing core body temperature. Int J Hyperthermia 34:1121-1133
Li, Dan; Fawaz, Maria V; Morin, Emily E et al. (2018) Effect of Synthetic High Density Lipoproteins Modification with Polyethylene Glycol on Pharmacokinetics and Pharmacodynamics. Mol Pharm 15:83-96
Yu, Minzhi; Benjamin, Mason M; Srinivasan, Santhanakrishnan et al. (2018) Battle of GLP-1 delivery technologies. Adv Drug Deliv Rev 130:113-130
Kong, Yen P; Rioja, Ana Y; Xue, Xufeng et al. (2018) A systems mechanobiology model to predict cardiac reprogramming outcomes on different biomaterials. Biomaterials 181:280-292
Morin, Emily E; Li, Xiang-An; Schwendeman, Anna (2018) HDL in Endocrine Carcinomas: Biomarker, Drug Carrier, and Potential Therapeutic. Front Endocrinol (Lausanne) 9:715
Guo, Yanhong; Yuan, Wenmin; Yu, Bilian et al. (2018) Synthetic High-Density Lipoprotein-Mediated Targeted Delivery of Liver X Receptors Agonist Promotes Atherosclerosis Regression. EBioMedicine 28:225-233
Tang, Jie; Li, Dan; Drake, Lindsey et al. (2017) Influence of route of administration and lipidation of apolipoprotein A-I peptide on pharmacokinetics and cholesterol mobilization. J Lipid Res 58:124-136
Fromen, Catherine A; Kelley, William J; Fish, Margaret B et al. (2017) Neutrophil-Particle Interactions in Blood Circulation Drive Particle Clearance and Alter Neutrophil Responses in Acute Inflammation. ACS Nano 11:10797-10807
Fish, Margaret B; Fromen, Catherine A; Lopez-Cazares, Genesis et al. (2017) Exploring deformable particles in vascular-targeted drug delivery: Softer is only sometimes better. Biomaterials 124:169-179
Rioja, Ana Y; Daley, Ethan L H; Habif, Julia C et al. (2017) Distributed vasculogenesis from modular agarose-hydroxyapatite-fibrinogen microbeads. Acta Biomater 55:144-152

Showing the most recent 10 out of 18 publications